Kazia Therapeutics Ltd completes Phase 2 study of glioblastoma drug Paxalisib; data to follow at conference

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has wrapped up its Phase 2 study of the glioblastoma treatment paxalisib. The company has received the final...

Related Keywords

China ,United States ,Canada , ,Triaxial Pty Ltd ,Kazia Therapeutics Ltd ,Dana Farber Cancer Institute ,Nasdaq ,James Garner ,Farber Cancer Institute ,Patrick Wen ,Novogen Limited ,Triaxial Pty ,